What statement should be reported to the primary healthcare provider before a scheduled percutaneous coronary intervention?

The statement that should be reported to the primary healthcare provider before a scheduled percutaneous coronary intervention is the one regarding taking metformin. This is particularly important because metformin is a medication used to manage blood sugar levels in patients with diabetes.

During a percutaneous coronary intervention, such as an angioplasty, contrast dye is often used to visualize the coronary arteries. There is a risk of lactic acidosis, a serious condition, when metformin is used in conjunction with procedures that involve the use of iodine-based contrast agents, especially if the patient has impaired kidney function. Therefore, informing the healthcare provider about the administration of metformin is crucial for ensuring the patient's safety and determining any necessary precautions, such as adjusting medications or monitoring renal function before and after the procedure.

While the other statements may contain information relevant to the patient's care, they do not present the same immediate risk associated with the use of contrast dye in conjunction with metformin. The allergy to shellfish is significant due to potential reactions to contrast dye, but it is less directly related to the medication management required for the procedure. Anxiety may be relevant for psychological support, and experiencing a warm sensation during the procedure is a normal response, but neither of these concerns necessitates immediate intervention compared to